newsfilter
← Latest News
GlobeNewswire·

Kaplan Fox is Investigating Claims on Behalf of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) Investors for Potential Securities Law Violations

  • Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL).
  • On November 3, 2026, Madrigal filed a Form 10-Q revealing a whistleblower complaint filed on October 9, 2026, alleging retaliation under the Sarbanes-Oxley Act.
  • The complaint stems from internal concerns raised by a former employee regarding data & reporting practices before their resignation in January 2026.
  • Madrigal disputes the allegations in the complaint & plans to vigorously defend itself.
  • Madrigal stock price declined 8.08% from $431.16 on November 2, 2026, to $396.32 on November 3, 2026.
  • Kaplan Fox is a securities litigation firm that has recovered over $10 billion for clients since its founding in 1956.
  • Investors who suffered losses or have information regarding the investigation may contact the firm via email or phone.
Company
Kaplan Fox & Kilsheimer, LLP
Keywords
Kaplan Fox & Kilsheimer, LLP, MDGL Investor Alert, MDGL Investigation, NASDAQ: MDGL, $MDGL, Shareholder Alert, Securities Investigation, Kaplan Fox, Class Action